Exhibit 99.1 ArriVent BioPharma Reports First Quarter 2024 Financial Results ● Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual Meeting ● Dosed first patient in Phase 1b combination study of firmonertinib and ICP-189 for advanced or metastatic non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) classical mutations ● Strong financial position with cash and cash equivalents of $317.4 million a ...